Gentiopicroside Ameliorates Oxidative Stress and Lipid Accumulation through Nuclear Factor Erythroid 2-Related Factor 2 Activation

Meiyu Jin,1 Haihua Feng,1 Yue Wang,2 Siru Yan,1 Bingyu Shen,1 Zheng Li,1 Haiyan Qin,1 Qi Wang,1 Jinxia Li,1 and Guowen Liu 1

1Key Laboratory of Zoonosis, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, Jilin 130062, China
2Department of Paediatric Hematology, The First Hospital of Jilin University, Changchun, Jilin 130021, China

Correspondence should be addressed to Guowen Liu; liuguowen2008@163.com

Received 15 March 2020; Accepted 10 April 2020; Published 17 June 2020

Academic Editor: Alin Cioica

Copyright © 2020 Meiyu Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The activation of nuclear factor erythroid 2-related factor 2 (Nrf2) is closely related to the alleviation of nonalcoholic fatty liver disease (NAFLD) by regulating oxidative stress and lipid homeostasis. Gentiopicroside (GPS), an iridoid glycoside found in the Gentianaceae, possesses anti-inflammatory and antioxidant effects. However, the protective effects of GPS on lipid accumulation and oxidative damage have not been investigated thoroughly in free fatty acid- (FFA-) induced HepG2 cells and tyloxapol- (Ty-) induced hyperlipidemia mice. Cell counting kit-8 assays, Oil Red O staining, Western blotting analysis, extraction of nuclear and cytosolic proteins, and biochemical index assay were employed to explore the mechanisms by which GPS exerts a protective effect on FFA-induced HepG2 cells and Ty-induced hyperlipidemia mouse model. This paper demonstrates that GPS could effectively alleviate NAFLD by elevating cell viability, reducing fatty deposition, downregulating TG, and activating nucleus Nrf2 in FFA-induced HepG2 cells. Meanwhile, GPS significantly regulated the activation of phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, Nrf2 antioxidant pathway, peroxisome proliferator-activated receptor α (PPARα), and GPS-inhibited sterol regulatory element-binding protein-1c (SREBP-1c) expression in FFA-stimulated lipid accumulation of HepG2 cells and Ty-treated mice. Interestingly, we highlight that PI3K/AKT inhibitor (LY294002) markedly increased the expression of Nrf2 antioxidant pathway, PPARα, and downregulated SREBP-1c in FFA-stimulated HepG2 cells. For these reasons, we found that the deletion of Nrf2 could lose the protective effects of GPS on the Nrf2 antioxidant pathway and PPARα activation and SREBP-1c inactivation in FFA-stimulated HepG2 cells and Ty-treated mice. GPS treatment had no effect on abnormal lipogenesis and antioxidant enzymes in Ty-induced Nrf2-/- mice. This work gives a new explanation that GPS may be a useful therapeutic strategy for NAFLD through upregulation of the Nrf2 antioxidant pathway, which can alleviate oxidative damage and lipid accumulation.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that is the commonest cause of chronic liver metabolic disease in Western countries. NAFLD not only increases the development of cardiovascular, type 2 diabetes mellitus, chronic kidney disease, and cardiac diseases but also increases the morbidity and mortality in patient with liver-related disease [1]. It is well known that NAFLD is an increasingly prevalent and high-incidence disease. In recent years, the “one-hit,” “two-hit,” and “multiple-hit” hypotheses have been used to explain the pathogenesis of NAFLD. And the “multiple-hit” hypothesis provides more precise explanations of NAFLD pathogenesis [2]. The “multiple-hit” hypothesis comprises (1) the insulin resistance, lipotoxicity, and disorder of fat metabolism caused by mitochondrial dysfunction, endoplasmic reticulum stress, and inflammasome activation; (2) the dysfunction of adipose tissue; (3) the genetic determinants; (4) the epigenetic factors; and (5) the dietary factors [2]. Importantly, simple accumulation of lipid plays a
key role in the development of NAFLD [3]. Moreover, abnormal lipid metabolism can produce lipotoxicity that induces oxidative stress [4]. Therefore, the present study will focus on the inhibition of the accumulation of lipid and oxidative damage.

In the liver of patients with NAFLD, patients can accumulate fat that is mainly in the form of triglycerides [5]. Triglycerides are synthesized through esterification of free fatty acids (FFAs) and glycerol. There have been studies highlighting FFA that can promote accumulation of lipid-derived toxic metabolites in HepG2 cells [6, 7]. And FFA treatment induced the overexpression of SREBP-1c that might be the main cause of β-cell production of lipotoxicity [8]. The previous work on peroxisome proliferator-activated receptor α (PPARα) has indicated that PPARα can regulate lipid and glucose metabolism in the treatment of dyslipidemia and diabetes [9]. Importantly, PPARα is crucial for fatty acid metabolic homeostasis in the liver and inhibiting the development of NAFLD [10]. Thus, activating PPARα and decreasing SREBP-1c may contribute to alleviating the lipid accumulation and lipotoxicity and inhibiting the development of NAFLD.

The nuclear factor erythroid 2-related factor 2 (Nrf2) is known as the “main regulator” of the antioxidant response that regulates the expression of hundreds of genes, such as SOD, GSH peroxidases, and catalase [11]. The antioxidant characteristics of Nrf2 can alleviate the development of numerous liver diseases [12–14]. For example, the Nrf2−/− mice promoted the happening of more oxidative stresses that induced the evolution of NAFLD to NASH comparing with the WT mice [15]. Recent studies have shown that many small molecule compounds play the functions of anti-inflammatory, antioxidant stress, and antiapoptosis by activating PPARα [16–18]. Some studies have found that S-propargyl-cysteine can protect MCD-induced fatty liver by the activation of Akt/Nrf2/HO-1 pathway [19]. Therefore, this study explored whether gentiopicroside (GPS) can improve the lipid toxicity and oxidative stress caused by triglyceride accumulation in hepatocytes through PPARα/Nrf2 signal.

GPS is extracted from roots and rhizomes of Gentiana-ceae, and iridoid glycosides are the main active component of GPS. Several researchers have theoretically investigated that GPS has the function of抗氧化 and liver protection [20, 21]. However, the association between GPS and PPARα/Nrf2 signal has not been investigated in NAFLD. In addition, tyloxapol (Ty), a surfactant, can increase triglyceride content in the blood and cause hyperlipidemia [22]. It has been found that Ty can cause the accumulation of triglycerides in the liver [23]. Many studies have used the NAFLD model induced by Ty for drug screening [24]. The current study confirmed that GPS treatment activated the PPARα/AKT and Nrf2 pathway in FFA-stimulated HepG2 cells and Ty-treated mice; however, Nrf2 pathway activation made a contribution to the antioxidant and alleviation lipid accumulation properties of GPS treatment, not the PPARα/AKT/Nrf2 pathway activation. These studies demonstrate that GPS ameliorated lipid accumulation through Nrf2 activation.

2. Materials and Methods

2.1. Materials. Gentiopicroside (GPS), purity ≥98%, was supplied by the Meilun Biotechnology (Dalian, China). Oleic acid, palmitic acid, and tyloxapol (Ty) were bought from Sigma (St. Louis, MO, USA). LY294002, a specific inhibitor of PI3K and AKT, was supplied by Cell Signal Technology (Beverly, MA, USA). TC, TG, ALT, AST, AOC, SOD, and MDA were offered by Jincheng Bioengineering Institute of Nanjing (Nanjing, China). GSH was obtained from Solarbio Science & Technology (Beijing, China). AKT and p-Akt were got from Affinity (Cincinnati, OH, USA). Antibodies against PI3K, p-PI3K, HO-1, and NQO1 were acquired from Cell Signal Technology (Beverly, MA, USA). Primary antibodies against Nrf2, β-actin, and LaminB came from Proteintech (Boston, MA, USA). GCLC, GCLM, and PPARα were from Abcam (Cambridge, MA, USA). SREBP-1c was obtained from Novus Biologicals (Littleton, CO, USA).

2.2. Cell Culture and Treatment. Cell lines of wild-type (WT) HepG2 and Nrf2−/− HepG2 were supported by China Cell Line Bank (Beijing, China) and Dr. Ci Xinxin (Institute of Translational Medicine, The First Hospital, Jilin University), respectively. These cells were grown in 4.5 g/L glucose DMEM (Gibco, NY, USA), 10% fetal bovine serum (FBS, Clark, Australia), and 1% penicillin/streptomycin (Meilun Biotechnology, Dalian, China) in a humidified 5% CO2/95% air atmosphere at 37 °C. These cells were pretreated with 4.5 g/L glucose DMEM (serum free) for 3 h before treatment.

WT HepG2 cells were exposed to 1 mM FFA (oleate : palmitate = 2 : 1) for different time points from 0 h to 24 h. WT HepG2 cells were incubated in 0, 4, 20, 100, 200, and 500 μM GPS for 24 h. The cells were cultured with GPS for 1 h; after that, the cells were coincubated with 1 mM mixture FFA for 24 h. Cytotoxicity of FFA and GPS was assayed using CCK-8 kits (Invigentech, CA, USA).

2.3. Oil Red O Staining. Cells and tissue sections were cleaned with PBS and then fastened with 4% paraformaldehyde (Servicebio, Wuhan, China) for 20-30 min and carbonyl for 1 min, respectively. After washing, cells and tissue sections were cultured with 60% isopropanol for 5 min and then dyed in 0.5% Oil Red O staining liquid (Sigma, MO, USA) for 10-20 min. The staining solution of cells and tissue sections was cleaned, then stained with hematoxylin stain (Solarbio Science & Technology, Beijing, China) for 1-2 min. The lipid droplet was observed by a light microscope.

2.4. Western Blot Analysis. Proteins were collected from the cells and hepatic tissue using RIPA (Beyotime, China) with phosphatase inhibitors (Thermo, USA) and PMSF (Beyotime, China). The proteins were separated on a 10% SDS-PAGE electrophoresis and then diverted to a polyvinylidene fluoride membrane. Dissected membranes were then sealed with the nonfat milk solution (5% w/v) for 1 h. After the membranes were adequately incubated with specific primary antibodies at 4 °C overnight, the membranes of proteins were further probed with the anti-rabbit or anti-mouse of HRP-conjugated antibodies (Boster, California, USA) for
1 h at room temperature. Finally, the bands of proteins were detected by super sensitive ECL chemiluminescence (Meilunbio, Dalian, China) and band intensities were analyzed using ImageJ gel analysis software.

2.5. Extraction of Nuclear and Cytosolic Proteins. The proteins of nuclear and cytoplasm were derived from the WT HepG2 cells using the Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, China). The extraction procedure is carried out according to the manufacturer’s instruction.

2.6. Animals and Treatment. WT female C57BL/6 mice were offered by the Liaoning Changsheng Biotechnology (production license: SCXK2010-0001; Liaoning, China). We used Nrf2-/- female C57BL/6 mice that were provided by The Jackson Laboratory (Bar Harbor, ME, USA). They were arranged in SPF environment at 24 ± 1 °C (relative humidity: 40%-80%), with a 12 h light and 12 h dark cycle. All mouse studies conformed to the U.S. National Institutes of Health (NIH), the Guide for the Care and Use of Laboratory Animals, and were authorized by the related ethnical regulations of Jilin University.

To estimate the protection effects of GPS in Ty-induced oxidative damage and lipid accumulation, WT mice were stochastically divided into seven groups: control (normal saline), Ty (500 mg/kg), GPS (20, 40, or 80 mg/kg)+Ty, GPS (80 mg/kg), and fenofibrate (100 mg/kg)+Ty. Nrf2-/- mice were divided randomly into control (normal saline) group, Ty (500 mg/kg) group, GPS (80 mg/kg) group, and GPS (80 mg/kg)+Ty group. All animals were hungered for 12 h and then given 80 mg/kg GPS by intraperitoneal injection. After 1 h, mice were treated by intraperitoneal injection of 500 mg/kg Ty for 12 h; after that, mouse serum and liver tissues were collected for the following researches.

2.7. Measurement of TC, TG, ALT, AST, AOC, GSH, SOD, and MDA Levels. To measure the accumulation of lipid in cell lysate and mouse serum, the content of TG was measured with commercial assay kits. TC levels in mouse serum were assayed with commercial assay kits. To examine the antioxidant capacity in mouse serum, commercial kits were used to measure AOC, GSH, and SOD levels.

2.8. Statistical Analysis. All data were presented as mean ± SD. One-way ANOVA and Tukey were used to assess statistical significance for multiple comparisons among the different groups. p < 0.05 was defined as significant. The statistical analyses and figures were performed using GraphPad Prism 7.

3. Results

3.1. FFA-Induced Lipid Accumulation and Cytotoxicity and Evaluation of GPS-Induced Cytotoxicity in HepG2 Cells. In order to evaluate the lipotoxicity model, HepG2 cells were exposed to 1 mM FFA (oleate : palmitate = 2 : 1) for different time points. As shown in Figure 1(b), FFA could induce extremely remarkable cytotoxicity at 24 h. Thus, we investi-
PI3K and AKT, while Nrf2, HO-1, NQO1, GCLM, and PPARα were significantly upregulated and SREBP-1c was significantly decreased in LY294002-induced and GPS-treated HepG2 cells (Figures 4(a)–4(i)). These findings suggested that PI3K and AKT phosphorylation could not enhance GPS treatment alleviating effects of oxidative stress and lipogenesis.

3.5. Deletion of Nrf2 Could Cause GPS-Induced Oxidative Stress and Lipogenesis in FFA-Stimulated HepG2 Cells. To further elucidate the precise molecular mechanism, we evaluated GPS-induced protective effects of oxidative stress and lipid deposition in FFA-stimulated HepG2 cells (Figures 4(a)–4(i)). These findings suggested that PI3K and AKT phosphorylation could not enhance GPS treatment alleviating effects of oxidative stress and lipogenesis.

3.6. GPS Treatment Promoted Nrf2 Expression in the Nucleus in FFA-Stimulated HepG2 Cells. Because of these findings in vitro, our further experiments explored whether GPS could elevate Nrf2 expression in the nucleus in FFA-stimulated HepG2 cells. As expected, GPS treatment markedly increased the FFA-stimulated expression of Nrf2 in the nucleus (Figures 6(a)–6(c)). These results confirmed that GPS may be a Nrf2 activator in FFA-stimulated HepG2 cells.

3.7. GPS Treatment Alleviated Oxidative Stress and Hepatic Lipogenesis in Ty-Induced Hyperlipidemia Mice. In order to
prove the protective mechanism of GPS treatment in vivo, we investigated whether GPS treatment could inhibit Ty-induced oxidative stress and hepatic lipogenesis in hyperlipidemia mice. Our results demonstrated that GPS treatment markedly elevated AKT phosphorylation and increased protein levels of Nrf2, HO-1, NQO1, and GCLM in Ty-induced oxidative stress mice (Figures 7(a)–7(f)). Consistently, GPS treatment remarkably activated PPARα and downregulated SREBP-1c in Ty-induced hepatic lipogenesis mice (Figures 7(a), 7(g), and 7(h)). Altogether, these results
Figure 3: Effects of GPS on FFA-stimulated lipogenesis, cytotoxicity, and oxidative stress in HepG2 cells. These cells were cultured with 200 μM GPS for 1 h and then treated with 1 mM FFA for 24 h. (a) Lipid accumulation was measured using the TG detection kit. (b) CCK-8 assay cell viability. (c) Representative photos of Oil Red O staining. (d) The levels of PI3K/AKT, Nrf2, HO-1, NQO1, GCLM, PPARα, and SREBP-1c were evaluated by Western blotting assays. (e–l) The expression of p-AKT was normalized to AKT; of p-PI3K was standardized to PI3K; and of Nrf2, HO-1, NQO1, GCLM, PPARα, and SREBP-1c was standardized to β-actin, respectively. All data are presented as mean ± SD (three independent experiments). *p < 0.05 and **p < 0.01 vs. control group; *p < 0.05 and **p < 0.01 vs. FFA-treated group.
indicated the protective effects of GPS treatment in vitro and in vivo.

3.8. Deletion of Nrf2 Could Inhibit GPS Treatment Protective Effects in Ty-Induced Hyperlipidemia Mice with Lipid Deposition and Oxidative Stress. To explicit whether the antioxidative stress and antilipogenesis effects of GPS-induced promoted Ty-induced hyperlipidemia mice by Nrf2 activation, we studied the Nrf2 knockout mice. As presented in Figures 8(a) and 8(b), GPS treatment reduced the serum of TC and TG in Ty-induced WT mice; however, these effects were markedly deprived in Ty-induced Nrf2-/- mice. Moreover, to assess the effects of GPS on Ty-induced oxidative damage, the content of ALT, AST, and SOD in the serum and AOC, GSH, MDA in the liver was measured by assay kits. Our results indicated that GPS treatment not only
and SREBP-1c was standardized to β-actin, and injected with Ty (500 mg/kg) for 12 h. (a) Western blot was used to analyze the levels of p-AKT, Nrf2, HO-1, NQO1, GCLM, PPARα, and SREBP-1c in the liver. (b–c) Measurement of Nucl-Nrf2/LaminB and Cyto-Nrf2/β-actin was quantified by densitometric analysis. All data are presented as mean ± SD (three independent experiments). **p < 0.01 vs. control group; ***p < 0.01 vs. FFA-treated group.

In addition, deletion of Nrf2 had the same effects on ALT, AST, and MDA levels but also significantly promoted AOC, GSH, and SOD contents in Ty-induced WT mice, whereas the levels of AOC, GSH, and SOD did not increase in Ty-induced Nrf2−/− mice (Figures 8(e)–8(g)). In addition, deletion of Nrf2 had the same effect on ALT, AST, and MDA in GPS treatment and Ty-induced mice (Figures 8(c), 8(d), and 8(h)). In Ty-induced Nrf2−/− mice, result of Oil Red O staining shown that GPS treatment could not inhibit the production of hepatic lipogenesis (Figure 8(i)).

Figure 6: GPS promoted Nrf2 expression in the nucleus. (a) Before 1 mM FFA treatment for 24 h, all HepG2 cells were incubated with 200 μM GPS for 1 h. The nuclear and cytoplasmic protein was extracted by a kit and analyzed by Western blotting. (b, c) Measurement of Nucl-Nrf2/LaminB and Cyto-Nrf2/β-actin was quantified by densitometric analysis. All data are presented as mean ± SD (three independent experiments). **p < 0.01 vs. control group; ***p < 0.01 vs. FFA-treated group.

Figure 7: Effects of GPS on the protein levels of AKT, Nrf2, HO-1, NQO1, GCLM, PPARα, and SREBP-1c in tyloxapol- (Ty-) treated mice. The Ty-induced mice were given by intraperitoneal injection with GPS (20, 40, or 80 mg/kg) or fenofibrate (100 mg/kg) for 1 h; after that, injected with Ty (500 mg/kg) for 12 h. (a) Western blot was used to analyze the levels of p-AKT, Nrf2, HO-1, NQO1, GCLM, PPARα, and SREBP-1c in the liver. (b–h) Quantification of p-AKT expression was standardized to AKT and of Nrf2, HO-1, NQO1, GCLM, PPARα, and SREBP-1c was standardized to β-actin, respectively. All data are presented as mean ± SD (n = 5, number of mice in each group). *p < 0.05 and **p < 0.01 vs. control group; *p < 0.05 and **p < 0.01 vs. Ty-stimulated group.

3.9. GPS Treatment Protective Effects in Ty-Induced Hyperlipidemia Mice Were Dependent on Activation of Nrf2. To make further efforts ascertain the exact mechanism about the oxidative stress and fatty degeneration of the liver of Nrf2, we investigated the levels of protein expression of GPS treatment in Ty-induced WT mice and Nrf2-/- mice. As presented in Figures 9(a)–9(e), GPS treatment inhibited Nrf2, NQO1, GCLC, and GCLM expression in Ty-induced Nrf2−/− mice but markedly activated in Ty-induced WT mice. Importantly, GPS treatment significantly activated PPARα
and downregulated SREBP-1c in Ty-induced WT mice but remarkably inhibited PPARα and upregulated SREBP-1c in Ty-induced Nrf2-/- mice (Figures 9(a), 9(f), and 9(g)). To conclude, our research results suggested that GPS can effectively alleviate Ty-induced oxidative stress and hepatic steatosis, which may be relied on markedly activation of Nrf2.

4. Discussion

The pathogenesis of NAFLD mainly includes intracellular fatty acid accumulation, oxidant stress, ATP depletion, and the function disorder of mitochondria [27]. It is noteworthy that, hepatic lipogenesis is increased, while fatty acid oxidation is insufficient that may promote oxidative stress. And oxidative stress can promote cellular damage and maintain the accumulation of lipids [3]. Nrf2, an oxidative stress-mediated transcription factor, has been suggested to be a target for the treatment of NAFLD [13]. Activation of Nrf2 inhibited FFA-induced oxidative damage [28]. Nrf2 can regulate the oxidant defense systems, mainly including the expression of stress response proteins HO-1; synthesis of reducing factors, such as GSH by GCLC and GCLM;
Nrf2-/- mice were administered 80 mg/kg GPS for 1 h. After the mice were subjected to 500 mg/kg Ty for 12 h. Western blot examined of Nrf2, NQO1, GCLC, GCLM, PPARα, and SREBP-1c in WT and Nrf2-/- mouse liver. (b) α-PPARff on the contrary, GPS treatment had no protective effe...
ALT, AST, and MDA (Figure 8). These results suggested that GPS might inhibit the hepatocyte apoptosis by activating the PI3K/Akt pathway. Unfortunately, we are unable to determine from these data that explained the enhanced antioxidant stress effects of GPS through inhibition of the PI3K/AKT pathway. This problem remains to be solved. Taken together, these data further support that GPS-inhibited oxidant stress may be associated with the Nrf2 activation and not the activation of the PI3K/AKT/Nrf2 pathway.

PPARα, a class of nuclear transcription factor, is activated by ligands that are fatty acid derivatives formed during fatty acid catabolism, lipogenesis, or lipolysis [36]. PPARα can improve steatosis and suppress the development of NAFLD [36]. SREBPs, the lipid synthetic transcription factors, have unique features for fatty acid and cholesterol synthesis [37]. According to the reports that activation of SREBP-1c promoted hepatic lipogenesis and aggravated NAFLD symptoms [38], recently, several reports revealed that regulating PPARα and SREBP-1c could ameliorate NAFLD. Park et al. found that Lonicera caerulea extract could inhibit the expression of SREBP-1c and upregulate PPARα expression in FFA-induced HepG2 cells and in diet-induced obese mice [39]. Importantly, GPS has been shown to upregulate PPARα and downregulate SREBP1 and TG in ethanol-treated HepG2 cells and alcoholic hepatosteatosis mice [40]. Our results similarly discovered that GPS treatment could remarkably activate PPARα and inhibit SREBP-1c and TG in FFA-induced HepG2 cells and Ty-induced mice (Figures 3 and 7). On the contrary, knockout of Nrf2 produced the reverse results (Figures 5 and 9). This is consistent with that Nrf2 which inhibits lipogenesis by regulating metabolic reprogramming during stress [41]. These results suggest that GPS-mediated Nrf2 can regulate lipid metabolism in FFA-induced HepG2 cells and Ty-induced mice.

In summary, we clarified that the PI3K/AKT pathway could not regulate the Nrf2 antioxidant pathway in GPS treatment. Moreover, our results suggest that HepG2 cells which knockout Nrf2 were susceptible oxidative stress and lipid accumulation in GPS treatment and FFA-induced HepG2 cells, the same as in GPS treatment and Ty-induced Nrf2-/- mice.

5. Conclusions

In conclusion, as shown in Figure 10, the current study demonstrated that GPS treatment strongly protected NAFLD against oxidative damage and lipid accumulation which were dependent on activation of the Nrf2 antioxidant pathway for the first time. This research offers a powerful testimony for the protective effects of GPS in the regulation of oxidative stress and lipid lipogenesis in NAFLD. For the protective effects of GPS in the regulation of oxidative stress and lipid lipogenesis in NAFLD. For the protective effects of GPS in the regulation of oxidative stress and lipid lipogenesis in NAFLD.

Abbreviations

| Abbreviation | Definition                   |
|--------------|------------------------------|
| AKT          | Protein kinase B             |
| ALT          | Alanine transaminase         |
| AOC          | Antioxidant capacity         |
| AST          | Aspartate aminotransferase   |
| CCK-8        | Cell counting kit-8          |
| FFA          | Free fatty acids             |
| GCLC         | Glutamate-cysteine ligase catalytic subunit |
| GCLM         | Glutamate-cysteine ligase regulatory subunit |
| GPS          | Gentiopicroside              |
| GSH          | Glutathione                  |
| HO-1         | Heme oxygenase-1             |
| MDA          | Malondialdehyde             |
| NAFLD        | Nonalcoholic fatty liver disease |
| NQO1         | NAD (P) H:quinone oxidoreductase |
Nrf2: Nuclear factor-erythroid 2-related factor 2
PI3K: Phosphatidylinositol 3-kinase
PPARα: Peroxisome proliferator-activated receptor α
SOD: Superoxide dismutase
SREBP-1c: Sterol regulatory element-binding protein-1c
TC: Total cholesterol
TG: Triglyceride
Ty: Tyloxapol.

Data Availability

The [DATA TYPE] data used to support the findings of this study are included within the article.

Additional Points

Publisher’s Note. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ethical Approval

All animal studies conformed to the U.S. National Institutes of Health (NIH), the Guide for the Care and Use of Laboratory Animals, and were authorized by the related ethical regulations of Jilin University.

Conflicts of Interest

Meiyu Jin, Haihua Feng, Yue Wang, Siru Yan, Bingyu Shen, Zheng Li, Haiyan Qin, Qi Wang, Jinxia Li declare that they have no conflicts of interest.

Authors’ Contributions

Meiyu Jin wrote the paper and performed the experiments; Haihua Feng, Guowen Liu, and Yue Wang provided research ideas; Siru Yan, Bingyu Shen, and Zheng Li analyzed the data; Haiyan Qin, Qi Wang, and Jinxia Li contributed to perform the experiments. All authors read and approved the final manuscript. Meiyu Jin, Haihua Feng, and Yue Wang contributed equally to this work.

Acknowledgments

This study was supported by grants from the National Nature Science Foundation of China (No. 31772798, No. 31970507, and No. 31672621).

References

[1] C. D. Byrne and G. Targher, “NAFLD: a multimystem disease,” Journal of Hepatology, vol. 62, no. 1, pp. S47–S64, 2015.
[2] E. Buzzetti, M. Pinzani, and E. A. Tsochatzis, “The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD),” Metabolism, vol. 65, no. 8, pp. 1038–1048, 2016.
[3] D. H. Ipsen, J. Lykkefeldt, and P. Tveden-Nyborg, “Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease,” Cellular and Molecular Life Sciences, vol. 75, no. 18, pp. 3313–3327, 2018.
[4] B. Sottero, S. Gargiulo, I. Russo, C. Barale, G. Poli, and F. Cavalot, “Postprandial dysmetabolism and oxidative stress in type 2 diabetes: pathogenetic mechanisms and therapeutic strategies,” Medicinal Research Reviews, vol. 35, no. 5, pp. 968–1031, 2015.
[5] M. M. Jacome-Sosa and E. J. Parks, “Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans,” Current Opinion in Lipidology, vol. 25, no. 3, pp. 213–220, 2014.
[6] M. R. Lee, K. I. Park, and J. Y. Ma, “Leonurus japonicus Houtt attenuates nonalcoholic fatty liver disease in free fatty acid-induced HepG2 cells and mice fed a high-fat diet,” Nutrients, vol. 10, no. 1, p. 20, 2018.
[7] O. Ali, H. A. Darwish, K. M. Eldieb, and S. A. Abdel Azim, “miR-26a potentially contributes to the regulation of fatty acid and sterol metabolism in vitro human HepG2 cell model of nonalcoholic fatty liver disease,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 8515343, 11 pages, 2018.
[8] J. Li, X. Liu, X. Ran et al., “Sterol regulatory element-binding protein-1c knockdown protected INS-1E cells from lipotoxicity,” Diabetes, Obesity & Metabolism, vol. 12, no. 1, pp. 35–46, 2010.
[9] P. Gervois, J. C. Fruchart, and B. Staels, "Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors," Nature Clinical Practice-Endocrinology & Metabolism, vol. 3, no. 2, pp. 145–156, 2007.
[10] A. Montagnier, A. Polizzi, E. Fouché et al., “Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD,” Gut, vol. 65, no. 7, pp. 1202–1214, 2016.
[11] B. M. Hybertson, B. Gao, S. K. Bose, and J. M. McCord, “Oxidative stress in health and disease: the therapeutic potential of Nrf 2 activation,” Molecular Aspects of Medicine, vol. 32, no. 4–6, pp. 234–246, 2011.
[12] D. Xu, M. Xu, S. Jeong et al., “The role of Nrf 2 in liver disease: novel molecular mechanisms and therapeutic approaches,” Frontiers in Pharmacology, vol. 9, article 1428, 2019.
[13] A. M. Bataille and J. E. Manautou, “Nrf 2: a potential target for new therapeutics in liver disease,” Clinical Pharmacology and Therapeutics, vol. 92, no. 3, pp. 340–348, 2012.
[14] S. M. Shin, J. H. Yang, and S. H. Ki, “Role of the Nrf2-ARE Pathway in Liver Diseases,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 763257, 9 pages, 2013.
[15] S. Chowdhry, M. H. Nazmy, P. J. Meakin et al., “Loss of Nrf 2 markedly exacerbates nonalcoholic steatohepatitis,” Free Radical Biology & Medicine, vol. 48, no. 2, pp. 357–371, 2010.
[16] L. Gu, P. Ye, H. Li et al., “Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE−/− mice by up-regulating heme oxygenase-1 via P13K/Akt/Nrf2/ARE pathway,” The FASEB Journal, vol. 33, no. 4, pp. 4836–4850, 2019.
[17] Z. Wen, W. Hou, W. Wu et al., “6′-O-Galloylpaeoniflorin Attenuates Cerebral Ischemia Reperfusion-Induced Neuroinflammation and Oxidative Stress via P13K/Akt/Nrf2 Activation,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 8678267, 14 pages, 2018.
[18] C. Y. Lu, Y.-C. Yang, C.-C. Li, K.-L. Liu, C.-K. Lii, and H.-W. Chen, “Andrographolide inhibits TNFα-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the P13K/Akt/Nrf2 and P13K/Akt/AP-1 pathways.
in human endothelial cells,” Biochemical Pharmacology, vol. 91, no. 1, pp. 40–50, 2014.

[19] W. Li, F. Ma, L. Zhang et al., “S-propargyl-cysteine exerts a novel protective effect on methionine and choline deficient diet-induced fatty liver via Akt/Nrf2/HO-1 pathway,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 4690857, 17 pages, 2016.

[20] K. Dai, X. J. Yi, X. J. Huang et al., “Hepatoprotective activity of iridoids, seco-iridoids and analog glycosides from Gentiana cruciata L. against carbon tetrachloride induced liver damage in rats,” Food & Function, vol. 5, no. 8, pp. 1795–1803, 2014.

[21] T. Ugawa, H. Kakuta, H. Moritani, O. Inagaki, and H. Shikama, “YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents,” British Journal of Pharmacology, vol. 139, no. 1, pp. 140–146, 2003.

[22] S. Uchiyama, J. Katarínc, D. Misić et al., “Hepatoprotective effects of secoiridoid-rich extracts from Gentiana cruciata L. against carbon tetrachloride induced liver damage,” Food & Function, vol. 5, no. 8, pp. 3171–3179, 2016.

[23] Y. Tian, H. Feng, L. Han et al., “Magnolol alleviates inflammatory responses and lipid accumulation by AMP-activated protein kinase-dependent peroxisome proliferator-activated receptor α activation,” Frontiers in Immunology, vol. 9, p. 147, 2018.

[24] R. Abdul-Ghani, V. Serra, B. Györffy et al., “The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1,” Oncogene, vol. 25, no. 12, pp. 1743–1752, 2006.

[25] H. Jiang, D. Fan, G. Zhou, X. Li, and H. Deng, “Phosphatidylinositol 3-kinase inhibitor (LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo,” Journal of Experimental & Clinical Cancer Research, vol. 29, no. 1, p. 34, 2010.

[26] M. Basaranoglu, G. Basaranoglu, and H. Senturk, “From fatty liver to fibrosis: a tale of ‘second hit’,” World Journal of Gastroenterology, vol. 19, no. 8, pp. 1158–1165, 2013.

[27] J. Feng, J. Luo, L. Deng et al., “Naringenin-induced HO-1 ameliorates high glucose or free fatty acids-associated apoptosis via PI3K and JNK/Nrf2 pathways in human umbilical vein endothelial cells,” International Immunopharmacology, vol. 75, article 105769, 2019.

[28] Q. Ma, “Role of nrf2 in oxidative stress and toxicity,” Annual Review of Pharmacology and Toxicology, vol. 53, pp. 401–426, 2013.

[29] X. Chen, H. Xue, W. Fang et al., “Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity,” Redox Biology, vol. 21, article 101068, 2019.

[30] Y. Cui, Q. Wang, X. Li, and X. Zhang, “Experimental nonalcoholic fatty liver disease in mice leads to cytochrome p450 2a5 upregulation through nuclear factor erythroid 2-like 2 translocation,” Redox Biology, vol. 1, no. 1, pp. 433–440, 2013.

[31] A. Prawan, J. K. Kundu, and Y. J. Surh, “Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection,” Antioxidants & Redox Signaling, vol. 7, no. 11-12, pp. 1688–1703, 2005.

[32] S. Zhuang, R. Yu, J. Zhong, P. Liu, and Z. Liu, “Rhein from Rheum rhabarbarum inhibits hydrogen-peroxide-induced oxidative stress in intestinal epithelial cells partly through PI3K/Akt-mediated Nrf 2/HO-1 pathways,” Journal of Agricultural and Food Chemistry, vol. 67, no. 9, pp. 2519–2529, 2019.

[33] J.-W. Han, X. R. Zhan, X. Y. Li et al., “Impaired PI3K/Akt signal pathway and hepatocellular injury in high-fat fed rats,” World Journal of Gastroenterology, vol. 16, no. 48, pp. 6111–6118, 2010.

[34] X. Jiang, X. Tang, P. Zhang, G. Liu, and H. Guo, “Cyanidin-3-O-β-glucoside protects primary mouse hepatocytes against high glucose-induced apoptosis by modulating mitochondrial dysfunction and the PI3K/Akt pathway,” Biochemical Pharmacology, vol. 90, no. 2, pp. 135–144, 2014.

[35] M. Pawlak, P. Lefebvre, and B. Staels, “Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 62, no. 3, pp. 720–733, 2015.

[36] H. Shimano, “Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes,” Progress in Lipid Research, vol. 40, no. 6, pp. 439–452, 2001.

[37] Y. Wang, J. Viscarra, S. J. Kim, and H. S. Sul, “Transcriptional regulation of hepatic lipogenesis,” Nature Reviews Molecular Cell Biology, vol. 16, no. 11, pp. 678–689, 2015.

[38] M. Park, J. H. Yoo, Y. S. Lee, and H. J. Lee, “Lonicera caerulea extract attenuates non-alcoholic fatty liver disease in free fatty acid-induced HepG2 hepatocytes and in high fat diet-fed mice,” Nutrients, vol. 11, no. 3, p. 499, 2019.

[39] X. Li, Y. Zhang, Q. Jin et al., “Liver kinase B1/AMP-activated protein kinase-mediated regulation by gentiopicroside ameliorates P2X7 receptor-dependent alcoholic hepatosteatosis,” British Journal of Pharmacology, vol. 175, no. 9, pp. 1451–1470, 2018.

[40] J. D. Hayes and A. T. Dinkova-Kostova, “The Nrf2 regulatory network provides an interface between redox and intermediary metabolism,” Trends in Biochemical Sciences, vol. 39, no. 4, pp. 199–218, 2014.